Robert A Lustig
Affiliation: University of Pennsylvania
- Imaging response in malignant glioma, RTOG 90-06Robert A Lustig
Hospital of the University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA 19104, USA
Am J Clin Oncol 30:32-7. 2007..This study compared patients treated with hyperfractionated radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to standard fractionation and BCNU...
- Long term responses with cetuximab therapy in glioblastoma multiformeRobert Lustig
Department of Radiation Oncology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, USA
Cancer Biol Ther 5:1242-3. 2006
- Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?Robert A Lustig
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Am J Clin Oncol 27:516-21. 2004....
- The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot StudySydney M Evans
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Transl Oncol 3:160-9. 2010..0291). In summary, patients had a worse prognosis if the [EF5/Ki-67(Binding)]/[Tumor(binding)] ratio was high. A hypothesis for the mechanisms and translational significance of these findings is discussed...
- Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assayKelly M MacArthur
Authors Affiliations Departments of Radiation Oncology and Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Cancer Res 74:2152-9. 2014..These results support further development of this assay as a generalized method to detect CTC in patients with cancer...
- Headache as a risk factor for neurovascular events in pediatric brain tumor patientsSarah M Kranick
Department of Neurology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Neurology 80:1452-6. 2013..To determine whether severe recurrent headache is a risk factor for neurovascular events in children who received radiation for brain tumors...
- Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placementPaul C McGovern
Division of Infectious Diseases, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, USA
Clin Infect Dis 36:759-65. 2003..Patients who received a Gliadel wafer had a higher incidence of infection than previously has been reported, and additional studies are required to better quantify this risk and describe the epidemiology of such infections...
- Noninvasive diffuse optical measurement of blood flow and blood oxygenation for monitoring radiation therapy in patients with head and neck tumors: a pilot studyUlas Sunar
Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6396, USA
J Biomed Opt 11:064021. 2006..0+/-8.1) [microM] at the end of the fourth week of therapy. These preliminary results suggest daily diffuse-optics-based therapy monitoring is feasible during the first two weeks and may have clinical promise...
- Treatment of pediatric intracranial arteriovenous malformations with linear-accelerator-based stereotactic radiosurgery: the University of Pennsylvania experienceAmit Maity
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Pediatr Neurosurg 40:207-14. 2004..Linear-accelerator-based SRS is effective in obliterating most AVMs in children; however, the potential for late effects exists, especially for those patients with larger target volumes...
- A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapyJames M Metz
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 4283, USA
Clin Cancer Res 10:6411-7. 2004..This phase Ib study was designed to evaluate the safety and side effect profile of topical Tempol in patients with brain metastases being treated with whole brain radiotherapy...
- Acute toxicity of proton beam radiation for pediatric central nervous system malignanciesGita Suneja
Department of Radiation Oncology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
Pediatr Blood Cancer 60:1431-6. 2013..Proton beam therapy (PBT) for pediatric CNS malignancies may reduce late toxicity, but acute toxicity is not well defined. We examined acute toxicity for children with CNS malignancies treated with PBT...
- A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversyCarol L Armstrong
Department of Neurology, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
Neuropsychol Rev 14:65-86. 2004..Furthermore, radiation effects appear severe only in a minority of patients. Risk is related to direct and indirect effects of cancer type, concurrent clinical factors, and premorbid risk factors...
- Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancerMitchell Machtay
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 59:72-7. 2004..We designed a prospective protocol to determine the feasibility, toxicity, and preliminary efficacy of a regimen of postoperative reirradiation, chemotherapy and the radioprotector amifostine after salvage head-and-neck surgery...
- Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing diseaseRobert Lustig
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Neuro Oncol 10:1004-9. 2008..R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM...
- Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting systemChristine E Hill-Kayser
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Electronic address
Pract Radiat Oncol 5:e417-22. 2015..Pediatric patients may receive complex treatment. In our department, an electronic incident reporting system (condition reporting system [CRS]) was developed and made available to all members...
- Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancerSarina B Elmariah
Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Breast J 12:470-4. 2006..We briefly discuss the incidence of BRCA-1 mutations in breast cancer as well as other primary neoplasms and consider potential mechanisms shared in the pathogenesis of breast and glial tumors...
- Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT)Mack Roach
University of California, San Francisco, San Francisco, CA Radiation Therapy Oncology Group, Philadelphia, PA Medical College of Wisconsin, Milwaukee, WI Hospital of the University of Pennsylvania, Philadelphia, PA Radiological Associates of Sacramento, Sacramento, CA SUNY Health Science Center, Brooklyn, NY Albert Einstein Medical Center, Philadelphia, PA Thomas Jefferson University Hospital, Philadelphia, PA Karmanos Cancer Institute, Wayne State University, Detroit, MI Oregon Health and Science University Knight Cancer Institute, Portland, OR Massachusetts General Hospital, Boston, MA Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA
J Clin Oncol 30:96. 2012..We update primary and secondary endpoints (SE): biochemical failure (BF), time to metastasis (Mets), prostate specific survival (PSS) and overall survival (OS)...
- Patterns of Failure for Pediatric Glioblastoma Multiforme Following Radiation TherapyJacob E Shabason
Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Pediatr Blood Cancer 63:1465-7. 2016..2%) were in-field, three (23.1%) were marginal, and one (7.7%) was distant. The majority of patients treated with adjuvant radiation failed in the region of high-dose RT, indicating the need for improvements in local therapy. ..
- Impact of image guidance during whole-brain radiation therapyEric Ojerholm
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania Electronic address
Pract Radiat Oncol 6:e345-e351. 2016..Radiation oncologists are rapidly adopting image-guided radiation therapy (IGRT), warranting further evaluation of its role and value. We analyzed the impact of IGRT for one of the most common radiation treatments...
- Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patientsSydney M Evans
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
J Neurooncol 127:391-400. 2016..Further studies will be needed to verify and further investigate the association between these two entities...
- Acute toxicity profile of patients with low-grade gliomas and meningiomas receiving proton therapyGenevieve Maquilan
Department of Radiation Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA
Am J Clin Oncol 37:438-43. 2014..Proton therapy is an emerging treatment modality. We studied its acute side effects on patients with low-grade gliomas and meningiomas...
- A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiformeMichelle Alonso-Basanta
Department of Radiation Oncology, Smilow Center for Translational Research 8 135, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Bldg 421, Philadelphia, PA, 19104, USA
J Neurooncol 116:365-72. 2014..NFV (1,250 mg bid) concurrent with temozolomide and radiotherapy is tolerated in most patients with glioblastoma. At the 1,250 mg bid dose level, patients should be monitored for hepatotoxicity and GI side effects...
- Phase measurement of cognitive impairment specific to radiotherapyCarol L Armstrong
Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 83:e319-24. 2012..The study design investigated semantic vs. perceptual and visual vs. verbal memory to determine the most disease-specific measure of RT-related changes and understanding of the neurotoxicity from RT to the brain...
- Recurrent late cerebral necrosis with aggressive characteristics after radiosurgical treatment of an arteriovenous malformation. Case reportH Isaac Chen
Department of Neurosurgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
J Neurosurg 105:455-60. 2006....
- Hypoxia is important in the biology and aggression of human glial brain tumorsSydney M Evans
Department of Radiation Oncology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
Clin Cancer Res 10:8177-84. 2004..1% oxygen) was present in 5 of 12 grade 4 tumors. A correlation between more rapid tumor recurrence and hypoxia was demonstrated with EF5 binding, but this relationship was not predicted by Eppendorf measurements...
- GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot studyJames Welsh
Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
Int J Radiat Oncol Biol Phys 68:159-65. 2007..To report on a retrospective analysis of the cumulative experience from eight institutions using the GliaSite Radiotherapy System as a brachytherapy boost in the initial management of glioblastoma multiforme...
- In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancerAndreea Dimofte
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Lasers Surg Med 31:305-12. 2002..To measure the fluence at tissue surface for patients in our Phase II clinical trial of motexafin lutetium (MLu)-mediated chest wall photodynamic therapy for recurrent breast carcinoma and to compare it to the calculated irradiance...
- Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fractionEmerson L Gasparetto
Division of Neuroradiology, Department of Radiology, Division of Neuro Oncology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
Radiology 250:887-96. 2009....
- GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysisArash J Gabayan
Department of Radiation Oncology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA
Neurosurgery 58:701-9; discussion 701-9. 2006..To review the cumulative experience of 10 institutions in treating recurrent malignant gliomas with the brachytherapy device, GliaSite Radiation Therapy System...
- Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcomeSydney M Evans
Department of Radiation Oncology, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6072, USA
Int J Radiat Oncol Biol Phys 69:1024-31. 2007..EF5, a 2-nitroimidazole hypoxia marker, was used to study the presence, levels, and prognostic significance of hypoxia in primary head and neck squamous cell tumors...